



Gabinete de Promoção dos  
Programa Quadro ID&I

# Porquê concorrer ao Horizonte 2020?

**Patrícia Calado, NCP Saúde**



# Gabinete de Promoção do Programa Quadro de I&DT

## GPPQ

[www.gppq.pt/h2020/](http://www.gppq.pt/h2020/)



**1º contacto**  
O que é o H2020  
Como funciona?



**Verificação da ideia**  
A minha ideia integra-se numa *call* do H2020?  
Onde?



**Preparação da proposta**  
Construção do consórcio, escrita da proposta, procura de parceiros, revisão da proposta



**Avaliação da proposta**  
por peritos independentes



**Assinatura do contrato**  
Procedimentos administrativos e legais




**Gestão do projeto**  
Relatórios, alterações ao contrato



**Relatórios, Exploração dos resultados**  
Auditorias da CE

# O QUE É O HORIZONTE 2020?



**80 B €**

**2014-2020**

# PORQUÊ CONCORRER AO H2020?

---




# VANTAGENS DA PARTICIPAÇÃO

---



- **Financiamento para ciência de excelência**
- **Abordagem a desafios globais e alinhamento da investigação com as políticas e objectivos estratégicos da UE**
- **Foco na inovação e acesso ao conhecimento gerado pelo consórcio**
- **Acesso a infra-estruturas de investigação de topo**
- **Acesso a redes de contactos, parcerias e colaborações em consórcios multidisciplinares**

# ESTRUTURA GERAL DO H2020





# OBJECTIVOS DO H2020 NA ÁREA DA SAÚDE

- Investir em “**melhor saúde** para todos”
- Manter as pessoas **idosas activas** e **independentes** por mais tempo
- Apoiar o desenvolvimento de **intervenções novas**, mais **seguras** e mais **eficazes**
- Contribuir para a **sustentabilidade** dos **sistemas de cuidados de saúde**



# FINANCIAMENTO – COMO FUNCIONA?

- Programas de Trabalho bienais
- Projetos em colaboração (mínimo 3 EM ou PA)





# H2020 – MAIOR SIMPLIFICAÇÃO

---

## 1. Regras iguais para todos os financiamentos H2020

(menos instrumentos e mais flexíveis)

## 2. Reembolso mais simples: 1 projeto = 1 taxa de reembolso

- X% dos custos elegíveis
- Taxa fixa de custos indirectos (25% dos custos elegíveis)

## 3. “Time to grant” mais curto

(8 meses após o deadline de submissão )




# PARTICIPAÇÃO PORTUGUESA NO H2020

---

- **Propostas: 4 710**
- **Projetos aprovados: 604**
- **Projetos coordenados: 159**
- **Participantes: 864**
- **Financiamento para PT**

**277 M€**

# PARTICIPAÇÃO PORTUGUESA NO H2020



# PARTICIPAÇÃO PORTUGUESA NO DS1

---


- **Propostas: 302**
- **Projetos aprovados: 39**
- **Taxa sucesso 13% (EU 9,5%)**
- **Projetos coordenados: 3**
- **Participantes: 46**
- **Financiamento para PT**

**14 M€**

# DS1 – Participação regional e institucional

## 2014-2015:

- 39 projectos
- 3 coordenações
- 46 participantes:
  - 16 Universidades
  - 8 Centros de Investigação
  - 10 Empresas (5 PME)
  - 12 Outros
- EU funding: 14 M€



# Em que projetos participamos?


---



# EURO-HEALTHY

- Shaping EUROpean policies to promote HEALTH equity
- **Universidade de Coimbra**, Portugal
- 14 partners (PT: Instituto Superior Técnico)
- 3 M€

Shaping EUROpean policies to promote HEALTH equity




Euro-Healthy

**Euro-Healthy**

- ▶ Home
- ▶ About Euro-Healthy
- ▶ Research
- ▶ Members
- ▶ Documents
- ▶ News
- ▶ Resources
- ▶ Euro-Healthy advisory board
- ▶ Staff Intranet
- ▶ Contact us

Like us on Twitter

[Tweet](#)



Horizon 2020


**Welcome to Euro-Healthy: "Shaping EUROpean policies to promote HEALTH equity"**

A three-year Horizon 2020 research project launched in January 2015 that aims to increase knowledge and **resources** on policies that have the potential to promote health and health equity across European regions with a focus on metropolitan areas. Euro-Healthy has eight **research work packages** and is formed by a consortia of **collaborating partner institutions**.

Within Euro-Healthy's objectives, the project will develop a **population health index** which will be supported by a **web-based geographic information system**. More information can be found in the **Euro-healthy informative leaflet**.


Euro-healthy partners participate in conferences, workshops and forums and disseminate project findings and collaborate with other related projects. These events are uploaded to the **news section**. You can also stay updated by reading the **Euro-Healthy newsletter**.

The NUTS (nomenclature of territorial units for statistics) level 2 map below includes the focal points participating in Euro-Healthy. Click on each city for detailed information.



# GrowMeUp

- GrowMeUp
- **Universidade de Coimbra, Portugal**
- 8 partners (PT: Cáritas Diocesana de Coimbra)
- 2.8 M€



The screenshot shows the GrowMeUp website homepage. At the top left is the logo, which features a stylized red robot head with a bar chart inside, followed by the text "growmeup" in a lowercase, sans-serif font. To the right of the logo is the European Commission logo, consisting of the European Union flag and the text "European Commission". Below the logo and flag is a text block: "This project has received funding from the European Union's Horizon 2020 research and innovation programme - Societal Challenge 1 (DG CONNECT/H) under grant agreement No 643647".


Below the header is a navigation bar with a blue "Home GrowMeUp" button on the left. To its right are links for "Dissemination", "Partners", "News", "Media Material", "« Join our community »", and "Login". On the far right of the navigation bar is a search box with a magnifying glass icon and the text "search...".

The main content area is divided into two columns. The left column contains a photograph of a group of people in a room. In the foreground, a person is seated in a wheelchair, looking at a small, white, cone-shaped robot on a table. Other people are standing and talking in the background. The right column contains a video player with the title "The GrowMeUp project" and a play button icon. Below the video player is a blue bar with the text "Social links".



# TREGeneration

- Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor
- **Instituto de Medicina Molecular, Portugal**
- 9 partners
- 6 M€



The screenshot shows the homepage of the TREGeneration website. At the top, there is a navigation bar with links for Home, News, Login, Sitemap, and Contact. The main header features the TREGeneration logo and a menu with links for THE PROJECT, THE TEAM, "THE PROBLEM", and DISSEMINATION. Below the header, there is a large image of a microscopic view of cells. On the left side, there is a "Latest News" section with two entries: "Second project meeting" and "GvH/GvL symposium". Below the news section, there is a "Welcome to the TREGeneration Website!" section with a paragraph of text and a "The TREGeneration partners" section with a map of Europe showing the locations of the project partners.

Home | News | Login | Sitemap | Contact

## TREGeneration

THE PROJECT THE TEAM "THE PROBLEM" DISSEMINATION

### Latest News

**Second project meeting**  
Another milestone has been reached.  
[Read more](#)

**GvH/GvL symposium**  
TREGeneration partner to host symposium and project meeting...  
[Read more](#)


### Welcome to the TREGeneration Website!

For patients with blood diseases such as acute leukemia, hematopoietic stem cell transplantation (HSCT) can be a curative treatment. At the same time, HSCT can cause serious complications when immune cells of the donor attack normal tissues of the patient. This reactivity of the donor against the patient, called graft versus host disease (GVHD), can be acute or chronic. Up to 50% of the patients submitted to HSCT can develop this complication. Whereas acute GVHD affects mostly the skin, the liver and the gastro-intestinal system, chronic GVHD is more insidious in onset and affects the skin, the mouth, the eyes, the gastric and intestinal mucosa, the liver, the lungs, the muscles and the genital tract.

All known pharmacological therapies for the treatment of this disease are often accompanied by severe side effects.

The EU Horizon 2020-funded research project TREGeneration now combines five parallel clinical studies in Europe and the USA in order to investigate a new, cell-based therapy wherein patients receive regulatory T cells from the donor in order to treat tissue damage due to GVHD.

### The TREGeneration partners



- Innovative approach for self-management and social welfare of Cystic Fibrosis patients in Europe: development, validation and implementation of a telematics tool.
- Fundacion para La Investigacion del Hospital Universitario la Fe de la Comunidad Valenciana, Spain
- 12 partners (PT: Faculdade de Medicina de Lisboa)
- 5 M€

**MY APP FOR Cystic Fibrosis**  
The management of CF in my hand

HOME ABOUT MYCYFAPP WHO WE ARE RESOURCES NEWS NEWSLETTER INTRANET MYFOODREC

**SUMMARY**

An accurate enzyme replacement arises as an early nutritional intervention able to provide better nutritional status and patients' welfare from early stages avoiding complications associated to the development of the disease. By means of our innovative and portable ICT tool we will improve the socio-economic impact of the disease, promoting healthy lifestyle, intertwining patient empowerment, education and training with self-management and prevention of secondary CF-complications. The multidisciplinary and complementary approach of this co-developed integrative PROJECT guarantees the patient's adherence to the treatment and the best outcome of the nutritional intervention mainly in childhood. The beneficiaries of the application comprise patients, caregivers, families and health professionals as well as health monitoring authorities. MyCyFAPP is tailored designed and will be clinically validated for CF self-management and monitoring becoming a competitive market product in Europe. This APP will have a key role as decision support system, boosting the growth and competitiveness of the participating SMEs in Europe, which will ensure the market uptake and the MyCyFAPP distribution for the benefit of the patient.

**OBJECTIVES**

It is to get to a scenario in which self-management of enzyme replacement in the European Cystic Fibrosis (CF) patients by means of a mobile application (APP) is progressively achieved and successfully implemented. The co-developed APP is aimed at a personalised and accurate control and monitoring of the disease thanks to the interaction between health professionals and patients.

**EXPECTED OUTCOMES**

1. Health and nutritional status improvement through a precise enzyme dosage.
2. Improved Quality of life both for patients and their families.
3. Economic savings both for the health system and for the patients' families.

MyCyFAPP, 2015 | Privacy | Contact

# FAIR-PARK-II

- Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone
- Centre Hospitalier Regional et Universitaire de Lille, France
- 15 partners (PT: Instituto de Medicina Molecular)
- 6 M€

FAIR PARK II

Conservative iron chelation as a disease modifying strategy in Parkinson's disease: a multicentric, parallel-group, placebo-controlled, randomised clinical trial of deferiprone

HOME ABOUT CONSORTIUM PATIENTS RESULTS NEWS AND EVENTS CONTACT US

**About Fair Park II**  
What is FAIR PARK II? What is Parkinson's Disease? What is iron chelation?

**Who?**  
Who is involved? Who are the patients? Can I get involved?

**Progress**  
Find out how we are getting on with the study through our regular updates

**News**

- The first patient has been enrolled at Lille's Hospital on February 9th 2016
- The FAIR PARK II annual meeting will be held in Berlin, Germany on June 23rd and 24th 2016
- The FAIR-PARK II kick-off meeting was held in Lille, France on 4-5 May 2015
- The final list of European expert centres for the clinical trial will be available in October 2015
- The final version of the study protocol, as submitting to regulators and ethics committees, will be available in January 2016.

**Patient Recruitment Countdown**

22nd March 2016  
Patients to be recruited  
336  
Patients recruited  
2

Find out more about Fair Park II from Prof David Devos, the project coordinator

# BETA3\_LVH

- A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease
- Universite Catholique de Louvain, Belgium
- 12 partners (PT: Faculdade de Medicina de Lisboa)
- 5.4 M€

**Beta3\_LVH: towards a treatment against heart failure**

Welcome Home Our Partners The clinical trial A bit of science... News FAQ

**The Beta3\_LVH project** Login/Sign up

Search site

Range 1  
Range 2  
Range 3

75%

Data 2  
Data 3

At the end of the study, echocardiography, MRI, and PET scan images will be correlated with the exercise capacity tests and the blood tests to interpret the results of the cohort of patients.

- Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease
- University College London, UK
- 14 partners (PT: Faculdade de Medicina de Lisboa)
- 6 M€



[Home](#) [Project Objectives](#) [Work Packages](#) [Consortium Partners](#) [News](#) [Contact](#)

## Clinical evaluation of nanoporous carbon adsorbent with tailored porosity (Yaq-001) as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease

WHO estimates that over 650 million people globally and more than 29 million European citizens suffer from a chronic liver condition with in excess of 170,000 European deaths from cirrhosis alone each year. Liver disease remains the 5<sup>th</sup> most common cause of death across Europe in individuals aged 45-65 years and costs more than €15.8bn per annum in total health costs and loss in economic productivity. Alarming increases in obesity rates and an ageing population mean that liver disease will become an even greater health concern for Europe over the next decade. The three major causes of liver disease, i.e. alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD) and viral hepatitis are amenable to prevention and treatment providing an opportunity to reduce the burden of liver disease in Europe and saving lives. Gut-derived endotoxemia and bacterial translocation play a central role in the pathogenesis of NAFLD, and the development of cirrhosis and its complications.

The academic-industrial consortium (CARBALIVE) has developed a novel strategy using nanoporous carbons of tailored porosity which is a cheap and safe approach that has been shown to reduce bacterial translocation and/or its products.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 634579.



### **Project Co-ordinator**

**Professor Rajiv Jalan.**

### *Professor of Hepatology*

*UCL Institute of liver and digestive diseases, UCL Medical School, Royal Free Hospital, Rowland Hill, London, NW3 2PF, UK*

*[E-mail: r.jalan@ucl.ac.uk](mailto:r.jalan@ucl.ac.uk)*

- Evidence-based ICT tools for weight loss maintenance
- Region Hovedstaden, Denmark
- 14 partners (PT: Univ Lisboa, Fac Motricidade Humana e Univ Coimbra)
- 5 M€



## ABOUT NOHOW

research in weight loss maintenance

Weight loss maintenance is difficult. We will learn how to help people do it.

Health problems associated with obesity are a major healthcare challenge. Effective interventions and successful commercial weight loss programmes to help people lose weight already exist. However, most people re-gain the weight they lose – weight loss maintenance is really difficult.

Researchers already know that weight loss maintenance (WLM) depends on changing behaviours. There are many techniques available to help people change their behaviour in the long term but we still don't know which of these techniques work best for WLM or why. We also don't know how different social and healthcare contexts influence the effectiveness of different techniques. To better tackle obesity and being



### WEIGHT LOSS MAINTENANCE (WLM)

Which techniques work best for WLM? The NoHoW team is working on strategies and predictors for WLM.



### CHANGING BEHAVIOUR

We need to learn more about how different people change their behavior to maintain their weight loss. At the moment, we don't know enough about how people maintain their weight loss, or why they regain weight, to develop really effective programmes for weight loss maintenance (WLM).



### NOHOW TOOLKIT FOR

- Evaluating mHealth technology in HIV to improve Empowerment and healthcare utilisation: Research and innovation to Generate Evidence for personalised care
- Brighton and Sussex University Hospitals NHS Trust, UK
- 13 partners (PT: Centro Hospitalar Lisboa Central)
- 5.5 M€

EmERGE mHealth platform

Search site

Home About Deliverables Contact Us

Patient reported outcomes will be used in the assessment and development of the system which aims to increase adherence and enable frailty to be reported using mHealth technology.

"Creating mHealth solutions to facilitate remote access to health care providers and

- Establishing the value and business model for sustainable eHealth services in Europe
- European Institute for Health Records, France
- 8 partners (PT: SPMS)



Establishing the value and business model for sustainable eHealth services in Europe

Welcome About Workplan Deliverables Consortium Contact us



Search



## Welcome

13/08/2015

VALUeHEALTH is an EU funded R&D project within the Horizon 2020 Framework Programme.

VALUeHEALTH is establishing how eHealth interoperability can create, deliver, and capture value for all stakeholders, to justify a sustainable market in scaling up cross-border interoperability. The consortium is developing an evidence-based business plan for sustainable interoperability, with sustainable revenue streams for developing and operating self-funding priority pan-European eHealth Services beyond 2020.

VALUeHEALTH comprises a rich multi-stakeholder consortium of experienced partners and funded experts, to bring together many essential viewpoints to undertake the work plan and - importantly - to endorse and champion its results.



Starting with the cross-border interoperability use cases already approved by the eHealth Network for the CEF [1], eight VALUeHEALTH partners cooperate with multiple stakeholders through a robust methodology to prioritise use cases relevant to Member States for cross-border and also within border health service business needs.

The consortium is

### Latest news

24 March 2016

[BioData World Congress 2016](#)

26-27 October 2016 Wellcome Genome Campus, Cambridge


### Supported by





# LIFEPATH

- Lifecourse biological pathways underlying social differences in healthy ageing
- Imperial College of Science Technology and Medicine, UK
- 13 partners (PT: Instituto Saúde Pública Universidade Porto)
- 6 M€



# SOUND

- Statistical multi-Omics UNDERstanding of Patient Samples
- European Molecular Biology Laboratory, Germany
- 10 partners (PT: Instituto Engenharia Mecânica)
- 3 M€

About SOUND

The Project

Work Packages

SOUND Consortium

Contact

SOUND



## About SOUND

SOUND is an international research project funded by the European Commission within its H2020 Research and Innovation programme “Personalising Health and Care”. Its objective is to create the bioinformatic tools for statistically informed use of personal genomic and other ‘omic data in medicine, including cancers and rare metabolic diseases. The partners comprise bioinformatician-statisticians and physician-scientists from leading institutions in personalized medicine including NCT and EMBL Heidelberg, ETH and University Hospital Zurich, TUM Munich

Search ...



### Recent Posts

📅 Clinical Bioinformatics as a Service  
– ECCB 2016 workshop

📅 Registration open: CSAMA 2016 –

# MedBioinformatics

- Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities
- Consorcio Mar Parc de Salut de Barcelona, Spain
- 9 partners (PT: BMD Software S.A.)
- 3.5 M€

INTRANET



HOME

PROJECT

CONSORTIUM

NEWS & MEDIA

RESULTS


USEFUL LINKS

CONTACT



### MedBioinformatics supported the ECTB 2016


The "1st European Conference on Translational Bioinformatics" (ECTB 2016) took place at the Ceremonial Hall of the University of Copenhagen during April 26-27. During these two days, 150 delegates and ...



### MedBioinformatics 4th General Assembly Meeting

The fourth General Assembly meeting of the MedBioinformatics project took place in Copenhagen on June 25th 2016. This short meeting was focused mainly on sustainability and business models, with an initial ...

- Integrated Monitoring of Vaccines Effects in Europe
- EPICONCEPT, France
- 25 partners (PT: Instituto Nacional de Saúde Dr Ricardo Jorge)
- 7.5 M€



**I-MOVE+**

**Work Packages**


- WP1: Scientific Coordination and Management
- WP2: Influenza Vaccines
- WP3: Pneumococcal vaccines
- WP4: Electronic databases and registries
- WP5: Cost-effectiveness analysis

Resources Influenza Vaccines  
Resources PCV vaccines  
I-MOVE+ publications  
Sitemap

**I-MOVE+ News**

- **1st Annual I-MOVE+ meeting, 20-24 June 2016, Veyrier du Lac, France.**
  - [Agenda, 20-21 June: pneumococcal vaccines](#)

*Countries participating in I-MOVE+*



I-MOVE+ (Integrated Monitoring of Vaccines in Europe) is a consortium of 26 partners (regional and national public health Institutes, SME, Universities from of 15 European Union / European Economic Area Member States.

Its goal is to develop a sustainable platform of primary care, hospital and laboratory networks that use validated standardised methods to evaluate existing and new vaccines programmes independently from commercial interests.

I-MOVE+ has received a grant (May 2015- Oct 2018) from the [European Commission \(H2020\)](#) to identify, pilot test, use, and disseminate the best study designs to measure, in near real time the effectiveness and impact of vaccines used in the elderly population to prevent influenza and pneumococcal infections.

# EUthyroid

- Towards the elimination of iodine deficiency and preventable thyroid-related diseases in Europe
- Universitätsmedizin Greifswald Körperschaft des Öffentlichen Rechts, Germany
- 32 partners (PT: Ministério da Defesa Nacional)
- 3 M€



HOME OUR GOALS PARTNERS TOOLS PRESS & MEDIA NEWS CONTACT

SEARCH


IMPRINT

## WELCOME TO EUthyroid

Currently Europe has no harmonised approach to ensure iodine intake of European citizens is sufficient to prevent health problems. EUthyroid is an EU-funded research project to evaluate current national efforts aimed at preventing iodine deficiency disorders. We aim to provide evidence for a cost effective harmonised approach to iodine prevention in Europe.

We are pleased to announce that Cyprus, Romania and Turkey have joined the EUthyroid project. They will provide relevant IDD monitoring data, thus

- Enhancing the effectiveness of programs and strategies to prevent youth smoking: a comparative realist evaluation of 7 European cities
- Academisch Medisch Centrum bij de Universiteit van Amsterdam, The Netherlands
- 10 partners (PT: Escola Nacional de Saúde Pública)
- 3 M€



## SILNE-R: Enhancing the effectiveness of strategies to prevent smoking in adolescents

Submitted by Dominique Nguyen on Thu, 01/21/2016 - 16:46

 [printer version](#)

### **SILNE-R** *SILNE-R, A three-year project funded by the European Commission through the Horizon 2020 programme*

Summary

The SILNE-R project aims to learn, by in-depth comparisons between seven European countries, how strategies and programmes to prevent youth smoking could enhance their effectiveness by taking into account the opportunities, barriers and resources present at local levels.

Top researchers from different disciplines and different European regions will be working in partnership and link up with international research networks concerned with tobacco control or young people's health. Together, they aim at generating the fine-grained much needed evidence to support decision makers in the implementation of smoking prevention strategies that are responsive to local conditions, effective in using available resources and inspired to reduce inequities.

#### Participating organisations and contact person

- University of Amsterdam (Netherlands) - Prof. Anton Kunst (coordinator)
- European Network of Smoking and Tobacco Prevention (Belgium) - Mr. Dominick Nguyen
- University of Maastricht (Netherlands) - Prof. Marc Willemsen
- Martin Luther University Halle-Wittenberg (Germany) - Prof. Matthias Richter

- Non-invasive monitoring of perinatal health through multiparametric digital representation of clinically relevant functions
- GCS Hopitaux Universitaires Grand Ouest, France
- 7 partners (PT: INESC-TEC)
- 4.5 M€

The screenshot shows the website interface for 'UNIVERSITE BRETAGNE LOIRE'. The top navigation bar includes links for 'Membres', 'Annuaire', 'Accès', 'Rechercher', and 'Espace presse'. The main header features the university logo and navigation options: 'MISSIONS ET ACTIVITÉS', 'ACTUALITÉS ET CHRONIQUES', 'UNIVERSITÉ BRETAGNE LOIRE', and 'OFFRE DE SERVICES'. The main content area is titled 'ACTUALITÉS ET CHRONIQUES' and features a large image of a woman's face. Below the image, the text reads: 'AMÉLIORER LA SANTÉ ET LE DEVENIR DES PRÉMATURÉS GRÂCE À DE NOUVEAUX OUTILS DE MONITORING ET DE DIAGNOSTIC'. A sidebar on the right contains a menu with categories: 'A la une', 'Actualités', 'Dossiers', 'Portraits', and 'Reportages'. Below the menu, there are sections for 'A CONSULTER' (with a link for 'Election de la ou du président(e) de la ComUE') and 'A TÉLÉCHARGER' (with a link for 'Communiqué de presse'). At the bottom of the main content area, there is a group photo of people.

- My Active and Healthy Aging
- Università Degli Studi di Torino, Italy
- 16 partners (PT: Associação Fraunhofer Portugal Research)
- 4.2 M€



Home

About us

Ageing & Frailty

Research

News & Events

Become a part of It

Press

Contact us





# i-PROGNOSIS

- Intelligent Parkinson eaRly detectiOn Guiding NOvel Supportive InterventioNS
- Aristotelio Panepistimio Thessalonikis, Greece
- 11 partners (PT: Faculdade de Motricidade Humana e PLUX - WIRELESS BIOSIGNALS S.A)
- 4 M€

i-PROGNOSIS

HOME THE PROJECT NEWS/EVENTS CONTACT FAQ

## An Horizon 2020 Project against Parkinson's

Intelligent Parkinson early detection guiding novel supportive interventions  
(more...)

LEARN MORE

### The i-PROGNOSIS Approach

- Early Parkinson's Detection**  
i-PROGNOSIS aims to develop early and unobtrusive Parkinson's disease...
- Supportive Interventions**  
i-PROGNOSIS plans to design interventions to help Parkinson's...
- Medical Evaluation**  
Detection tests & interventions will be evaluated by our medical experts to...

Transmissão

# INHERIT

- INter-sectoral Health Environment Research for InnovaTions
- Eurohealthnet ASBL
- 18 partners (PT: Instituto Universitário de Lisboa)
- 6 M€



[ABOUT](#) [PROJECT](#) [IDEAS](#) [MEDIA](#)



# UM Cure 2020

- New therapies for uveal melanoma
- Institut Curie, France
- 12 partners (PT: Fundação Champalimaud)
- 6.2 M€

The screenshot displays the Institut Curie website. At the top, the logo and slogan "Together, let's beat cancer" are visible. A navigation bar includes "INSTITUT CURIE", "CARE", "RESEARCH", and "TRAINING". A search bar is present with the text "SOMETHING" and "PEOPLE". A "DONATE NOW" button is located in the top right. The main content area features a news article titled "INSTITUT CURIE AND PARTNERS HAVE BEEN AWARDED A EUROPEAN H2020 GRANT ON UVEAL MELANOMA". The article text states: "Institut Curie is the French referral centre coordinator for the treatment of uveal melanoma, a rare cancer of the eye. And now it is also the European coordinator of a consortium dedicated to the improvement of basic, translational and clinical research on the most common primary intraocular malignancy in adults." Below the text is a photo of an elderly man's eye with the caption "© Phovoir". Further text explains that although uveal melanoma is common in adults, it is a rare cancer with low incidence, requiring highly specialized treatment. Each year, Institut Curie cares for 300 new patients with melanoma of the eye. Key objectives include preserving vision through conservative treatments like surgery, protontherapy, and brachytherapy. The article also mentions a "A European H2020 grant on uveal melanoma" and states that the overall goal of the "UM Cure 2020" project is to increase knowledge in uveal melanoma metastases by identifying and validating preclinical level novel therapeutic approaches. The project involves dedicated clinical trials sponsored by academia or pharma, led by Dr. Sergio Roman-Roman, Head of Institut Curie's Department of Translational Research, who brings together experts in uveal melanoma in both patient care and basic/translational/clinical research, along with several European Centres of Excellence in clinical Ocular Oncology and the patient organization Melanoma Patient Network.

On the right side of the website, there are several utility buttons: "JOIN US" with a person icon, "PRESS AREA" with a pencil icon, "NEWSLETTER" with an envelope icon, "PRATICAL INFORMATIONS" with a location pin icon, and "SUPPORT US" with a heart icon. Below these is a "Prendre rendez-vous" button with a calendar icon.

**Will YOU be next?**



[patricia.calado@gppq.pt](mailto:patricia.calado@gppq.pt)

**911836453**

**[pt.linkedin.com/in/patriciacalado](https://pt.linkedin.com/in/patriciacalado)**